Home » Newsletters » BioWorld Science

BioWorld Science

June 21, 2021

View Archived Issues

LZM-005 shows safety, potent activity in phase I study in HER2-positive metastatic breast cancer

Phase I dose-escalation data for SAR-439459 as monotherapy or in combination with cemiplimab

Etavopivat improves hematologic and hemolytic parameters in patients with sickle cell disease

Pfizer studies PF-07202954 in phase I healthy volunteer trial for NAFLD

Targeting FKBP5 lowers huntingtin levels by inducing autophagy in Huntington's disease models

OTUD7A: a novel therapeutic target for Ewing sarcomas with EWS-FLI1 fusions

Canopy Growth divulges new cannabinoid CB1 and CB2 receptor modulators

Bayer and DKFZ synthesize new DGKA inhibitors

Chinese researchers present CEACAM5- and CD3-targeting antibodies for cancer

Mavorixafor and ibrutinib in WM with MYD88 and CXCR4 mutations

NIH grant supports Praetego's development of AGE inhibitors

Evergreen prepares for phase II trial of COVID-19 candidate EG-009A

Ociperlimab shows safety and preliminary antitumor activity in combination with tislelizumab

French clearance for phase I/IIa trial of PBP-1510 for pancreatic cancer

LncRNA HOST2 is a diagnostic marker in TNBC

Topline phase II data for nezulcitinib in patients hospitalized with ALI due to COVID-19

Tonix to study TNX-102 SL for the treatment of long COVID syndrome

Period piece: endometrial organoids from menstrual blood

SIGMAR1 mRNA identified as biomarker of response in phase II study of blarcamesine

First subject enrolled in OLYMPIA phase II study of OC-01

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...